Latest News

Rising patient interest in TRT, GLP-1s, and peptide stacking requires clinicians to anchor conversations in evidence tiers, use baseline DEXA scans to monitor body composition, and engage patient goals without endorsing unsupported claims.

Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.

Higher saturated and animal fat intake was linked to increased mortality after nonmetastatic prostate cancer, according to a cohort study published in JAMA Network Open.

In this episode, Surena F. Matin, MD, FACS, discusses the evidence and practical considerations surrounding perioperative intravesical chemotherapy to reduce bladder recurrence after nephroureterectomy.

The FDA has provided an update on efforts to increase supply of estradiol transdermal patches as demand increases.

NeoBLAST, a phase 2/3 Canadian trial, tests whether active surveillance can safely replace surgery/radiation in MIBC patients with complete response to neoadjuvant therapy.

This episode explores evolving approaches to sexual wellness, innovation in premature ejaculation, the need for patient education, and integrating sexual health products into clinical care across the lifespan.

Martin Schoen, MD, PhD, discusses how study methodology, patient selection, and confounding can shape real-world evidence findings in prostate cancer.

In this Q&A, Shiv B. Patel, MD, reflects on how prostate cancer screening has evolved from a one-size-fits-all approach to a more individualized strategy.

Routine cardiovascular specialist referral improved cholesterol control in patients with prostate cancer but did not reduce cardiovascular events.

LUGPA CEO Celeste Kirschner, CAE, MHSA, outlines the association's top 2027 priorities: fee schedule reform, site-neutral payments, prior authorization, and practice consolidation.

Martin Schoen, MD, PhD, discusses factors guiding ARPI selection in prostate cancer and how real-world evidence can help inform treatment decisions.

Closing racial disparities in prostate cancer requires meeting men in barbershops, churches, and community screenings—not just clinics, according to Justin Cohen, MD.